Proteomics International Laboratories Ltd (ASX: PIQ) Share Price and News

Mr House has over 30 years of experience with multi-national corporations and is currently the CEO and Managing Director of Imdex. He previously served eight years as the Managing Director of SGS India, where he was responsible for a workforce of 4,500 personnel and 38 laboratories; SGS is the world's leading Testing, Inspection and Certification (TIC) company.

Dr Williams is a manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Over the past 25 years, as an established entrepreneur, he has been involved from startup to commercialisation, including CEO, CTO, Director and Chair roles, of numerous biotech companies which have resulted in five Food and Drug Administration (FDA) approved drugs and medical devices. He conceived the technology behind iCeutica Inc (acquired in 2011) and co-discovered the lead therapy for ASX-listed Dimerix Limited (ASX:DXB), now in Phase 3 trials for Chronic Kidney Disease. Dr Williams is currently CEO of Health Translation Group Ltd, a not-for-profit company focusing on translation of medical research outcomes, a Director of the Perron Institute for Neurological and Translational Science and agriculture start-up Demagtech, and a member of the WA State Governments Health and Medical Life Sciences Industry Advisory Group. He was previously co-founder and Investment Director of early-stage VC firm Yuuwa Capital, and appointed director on several portfolio companies, a Director of clinical trial facility Linear Clinical Research and a member of the Australian Federal Governments Entrepreneurs Program Committee.

Dr Lipscombe has expertise in chemistry, immunology, mass spectrometry, peptide synthesis, high performance computing and robotics. Richard has international experience in both science and business gained over a 30-year period in Australia, USA and the UK, including work in hospital and academic laboratories and commercial organisations.

Mr Gardiner is a finance professional with over 30 years of experience advising Boards of public and private companies on mergers and acquisitions, project development, equity and debt capital markets, transaction structuring, capital allocation and complex commercial problem solving.

Mr Brinkworth is a former biopharmaceutical executive with 25 years industry experience. Over a 22-year career at Gilead Sciences, Inc. (Nasdaq: GILD), he held senior commercial, patient access and strategic licensing roles. He managed geographically dispersed teams and business partners across 31 countries and is experienced in building strategic partnerships with industry leaders, government officials and non-government organisations. Mr Brinkworth currently serves as non-executive Director for Resonance Health Ltd (ASX: RHT).

-

-